PeptideInfo
Back to Directory

Tropisetron

Phase II Trials

Also known as: Navoban, ICS 205-930

Prescription Only — FDA Approved Medication

Educational Content Only

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The FDA has not evaluated many of the peptides discussed here. Always consult a licensed healthcare provider before making any health decisions.

Overview

Tropisetron is a 5-HT3 receptor antagonist and alpha7 nicotinic acetylcholine receptor agonist approved in various countries for chemotherapy-induced nausea. Research has also examined its potential roles in pain management, fibromyalgia, and cognitive enhancement through its dual receptor pharmacology.

Possible Uses

The following areas have been examined in research contexts. This does not constitute medical advice or imply proven efficacy in humans.

  • Immune Support
  • Cognitive Enhancement
Mechanism of Action

Blocks 5-HT3 receptors to reduce nausea and pain signaling, while acting as a partial agonist at alpha7 nicotinic receptors. Alpha7 nAChR agonism has been studied in the context of cognitive enhancement, anti-inflammatory effects, and synaptic plasticity.

Safety Notes

Approved in multiple countries for CINV. Not FDA-approved in the US. Well-characterized safety profile from oncology use. CNS effects possible.

Research Profile

Half-Life

~8 hours

Administration

oral, intravenous (clinical)

Legal Status (US)

Approved in multiple countries. Not FDA-approved in the US.

12 indexed research passages

Categories
Cognitive & NeurologicalImmune & Inflammation
Research Interest Areas
Immune SupportCognitive Enhancement